The project is led by Alexandre Corthay and has been granted 9 million NOK over a period of three years (2022-2025) from the South-Eastern Norway Regional Health Authority (Helse Sør-Øst).
HTH group leader Alexandre Corthay receives funding from the South-Eastern Norway Regional Health Authority
The project is entitled “Unleashing the full antitumor potential of macrophages for next-generation cancer immunotherapy”and a central part of this project will be to establish and use tumor on-a-chip technology at HTH.
Published Jan. 20, 2022 11:14 AM
- Last modified Jan. 20, 2022 11:18 AM